Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia
- 30 June 2010
- journal article
- research article
- Published by Elsevier BV in Clinical Biochemistry
- Vol. 43 (9), 768-770
- https://doi.org/10.1016/j.clinbiochem.2010.02.010
Abstract
No abstract availableKeywords
Funding Information
- Roche Diagnostics
This publication has 11 references indexed in Scilit:
- Technical performance of the first fully automated assays for human soluble fms-like tyrosine kinase 1 and human placental growth factorZeitschrift für Geburtshilfe und Neonatologie, 2009
- Placental Growth Factor and Soluble FMS-Like Tyrosine Kinase-1 in Early-Onset and Late-Onset PreeclampsiaObstetrics & Gynecology, 2007
- Soluble Endoglin and Other Circulating Antiangiogenic Factors in PreeclampsiaThe New England Journal of Medicine, 2006
- Circulating Angiogenic Factors in the Pathogenesis and Prediction of PreeclampsiaHypertension, 2005
- Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsiaEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2005
- Latest Advances in Understanding PreeclampsiaScience, 2005
- Maternal Serum sFlt1 Concentration Is an Early and Reliable Predictive Marker of PreeclampsiaClinical Chemistry, 2004
- Circulating Angiogenic Factors and the Risk of PreeclampsiaThe New England Journal of Medicine, 2004
- Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsiaJCI Insight, 2003
- Pathogenesis and genetics of pre-eclampsiaThe Lancet, 2001